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OPEN ACCESS
IMPROVE trial investigators
Abstract
Objective To assess whether a strategy of endovascular repair (if aortic
morphology is suitable, open repair if not) versus open repair reduces
early mortality for patients with suspected ruptured abdominal aortic
aneurysm.
Design Randomised controlled trial.
Setting 30 vascular centres (29 UK, 1 Canadian), 2009-13.
Participants 613 eligible patients (480 men) with a clinical diagnosis of
ruptured aneurysm.
Interventions 316 patients were randomised to the endovascular
strategy (275 confirmed ruptures, 174 anatomically suitable for
endovascular repair) and 297 to open repair (261 confirmed ruptures).
Main outcomemeasures 30 day mortality, with 24 hour and in-hospital
mortality, costs, and time and place of discharge as secondary outcomes.
Results 30 day mortality was 35.4% (112/316) in the endovascular
strategy group and 37.4% (111/297) in the open repair group: odds ratio
0.92 (95% confidence interval 0.66 to 1.28; P=0.62); odds ratio after
adjustment for age, sex, and Hardman index 0.94 (0.67 to 1.33). Women
may benefit more than men (interaction test P=0.02) from the
endovascular strategy: odds ratio 0.44 (0.22 to 0.91) versus 1.18 (0.80
to 1.75). 30 day mortality for patients with confirmed rupture was 36.4%
(100/275) in the endovascular strategy group and 40.6% (106/261) in
the open repair group (P=0.31). More patients in the endovascular
strategy than in the open repair group were discharged directly to home
(189/201 (94%) v 141/183 (77%); P<0.001). Average 30 day costs were
similar between the randomised groups, with an incremental cost saving
for the endovascular strategy versus open repair of £1186 (€1420; $1939)
(95% confidence interval −£625 to £2997).
Conclusions A strategy of endovascular repair was not associated with
significant reduction in either 30 day mortality or cost. Longer term cost
effectiveness evaluations are needed to assess the full effects of the
endovascular strategy in both men and women.
Trial registration Current Controlled Trials ISRCTN48334791.
Introduction
Ruptured abdominal aortic aneurysm remains one of the most
common vascular emergencies, even though mortality from
ruptured aneurysm has been declining at the population level.1
Without repair, ruptured aneurysm is nearly always fatal.2 The
30 day mortality from emergency open repair has remained at
nearly 50% for many years,3 4 but findings from national datasets
suggest that emergency endovascular aneurysm repair (EVAR)
may be associated with a lower 30 day mortality rate of about
30%.4-6 Such data may be subject to major confounding bias.
Many patients with ruptured aneurysm have aortic morphology
that is unsuitable for conventional EVAR. Observational studies
do not consider centres’ expertise, which potentially influences
selection of patients and diagnostic criteria.
Two small randomised trials of EVAR versus open repair for
ruptured abdominal aortic aneurysm have reported on 30 day
mortality. The first of these was a pilot, single centre trial in 32
patients in Nottingham, England, in which the overall mortality
was over 50%.7 A three centre trial in 116 patients in the
Netherlands reported recently.8 This trial randomised patients
only after local confirmation of both rupture of aneurysm and
anatomical suitability for EVAR and therefore excluded
haemodynamically unstable patients. Neither trial has published
economic evaluations nor shown any difference in 30 day
mortality between the EVAR and open repair groups (21% and
25% respectively in the Dutch trial).8 The low mortality rates
in the Dutch trial have been attributed to the presence of
specialist teams and patients’ characteristics (relative
haemodynamic stability and anatomy favouring repair by both
open and endovascular methods).
Debate is ongoing about how to configure hospital services to
ensure equitable access to complex emergency surgery.
Improving the variable outcomes for ruptured aneurysm repair,
seen in several countries,5-10 typifies the challenge in providing
24/7 access to high quality emergency surgery based on robust
evidence. The logistics of providing an endovascular service
for ruptured abdominal aortic aneurysm are formidable with
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regard to the availability of appropriate personnel, facilities,
and consumables. Whether patients with clinical suspicion of
rupture should be referred to a centre providing a comprehensive
endovascular service and how widely such services should be
available, to optimise both patients’ outcomes and organisation
of services, are therefore unclear. The Immediate Management
of Patients with Rupture: Open Versus Endovascular Repair
(IMPROVE) trial aims to answer this question and tests the
hypothesis that a strategy of endovascular repair, if anatomically
feasible, reduces the 30 day mortality of patients with a clinical
diagnosis of ruptured abdominal aortic aneurysm, compared
with treatment by open repair.
Methods
Study design
IMPROVE is a multicentre trial that randomised patients with
a clinical diagnosis of ruptured abdominal aortic aneurysm to
either an endovascular strategy of immediate computed
tomography and emergency EVAR,with open repair for patients
anatomically unsuitable for EVAR (endovascular strategy
group), or to the standard treatment of emergency open repair
(open repair group). This trial was conducted in 29 eligible
centres in the United Kingdom and one in Canada. The
eligibility of each centre to participate in the trial was determined
by their clinical credentials, including audited volumes of
elective EVAR of more than 20 cases a year out of at least 50
cases of aortic surgery, evidence of good interdisciplinary team
working, availability of the team for at least 66% of the week,
rapid access to emergency computed tomography (target 20
minutes), and audited experience of emergency EVAR
(minimum of five cases). The trial protocol, guidelines, and
statistical analysis plan are available on the trial websites (www.
imperial.ac.uk/medicine/improvetrial or www.improvetrial.org).
All patients aged over 50 years with a clinical diagnosis of
ruptured abdominal aortic aneurysm or ruptured aorto-iliac
aneurysm, made by a senior trial hospital clinician (either in
emergency medicine or vascular surgery), were recorded and
were eligible for inclusion. The first brief consent process could
be written, verbal, or (if necessary, in England) by using the
Mental Capacity Act 2005. Patients were re-consented, for
continued participation in the trial, during the recovery period.
We excluded patients if they had a previous aneurysm repair,
rupture of an isolated internal iliac aneurysm, aorto-caval or
aorto-enteric fistulae, recent anatomical assessment of the aorta
(for example, awaiting elective EVAR), or a connective tissue
disorder or if intervention was considered futile (patient
moribund).
Randomisation
An independent contractor provided telephone randomisation,
with computer generated assignation of patients in a 1:1 ratio,
using variable block size and stratified by centre. Date and time
of randomisation together with type of initial consent
(written/verbal/other) were recorded automatically. The
randomisation was confirmed by email to the trial manager, the
principal investigator at the site, and the trial coordinator.
Patients were randomised either to an endovascular strategy
(immediate computed tomography followed by EVAR if locally
determined as anatomically suitable and open repair when not
suitable) or to immediate open repair with computed tomography
being optional. As this was a surgical trial, neither investigators
nor patients could be masked to the treatment allocated.
Adherence to the allocated treatment group was reinforced
wherever possible by onsite training and newsletters.
Data verification, computed tomography core
laboratory, and diagnosis
All consents were audited, and a minimum of 15% of patients
at each centre had source data verified. Computed tomography
scans on admission were sent for analysis in the trial core
laboratory (St George’s Hospital, London) and were subject to
expert review for the presence of rupture. Rupture of aneurysm
was defined according to protocol. Briefly, evidence on
computed tomography of the presence of blood or haematoma
outside the aneurysm wall (abdominal aorta, common iliac
artery, or both) constituted a diagnosis of ruptured aneurysm.
In patients without computed tomography, the diagnosis of
rupture was made intraoperatively. In those without either
computed tomography or laparotomy, diagnosis was from the
underlying cause of death provided. All patients randomised in
the UKwere registered to obtain automatic reporting of the date
and cause of death from the national Data Linkage Service.
Patients admitted with symptoms referable to an abdominal
aortic aneurysm but no proven evidence of aorto-iliac rupture
(core laboratory diagnosis or laparotomy findings) who
underwent repair semi-electively in the same admission were
categorised as symptomatic, non-ruptured aneurysm. Other
patients had primary hospital discharge diagnoses unrelated to
abdominal aortic aneurysm.
Outcomes and oversight
The primary outcome was survival at 30 days after
randomisation. The trial, comparing the groups as randomised,
had more than 90% power to detect (as significant at 5%) a
difference in 30 daymortality of 14%with 600 patients enrolled.
This was based on estimated 30 day mortalities of 47% for
patients receiving open repair and 21% for those receiving
EVAR,3 11 an estimate of 55% of patients being anatomically
suitable for EVAR after computed tomography, and that 5% of
both randomised groups would not have a proven diagnosis of
ruptured abdominal aortic aneurysm.7 Hence, estimated 30 day
mortality was 44.7% in the open repair group and 30.4% in the
endovascular strategy group.
Secondary outcomes reported here include 24 hour mortality,
in-hospital mortality, costs of primary admission,
re-interventions during the primary admission, and time and
place to which discharged from the trial hospital. Mortality and
cost effectiveness at 12 months are secondary outcomes
scheduled for future reporting.
An independent data monitoring committee reviewed the data,
with interim analyses after enrolment of 50, 200, and 400
patients, and agreed that continuing the trial was safe.
Statistical analysis
We analysed data according to a pre-specified analysis plan
(available on trial websites), and all analyses, except the causal
analysis, were by intention to treat. The primary analysis
assessed the difference in the proportion surviving 30 days
between the randomised groups, following an intention to treat
policy and using a Pearson’s χ2 test without continuity
correction. We then adjusted the primary outcome for sex, age,
and Hardman index by using logistic regression (with the last
two variables considered as continuous), providing an adjusted
odds ratio. The Hardman index is a validated risk scoring system
for ruptured aneurysms.12 13 We multiply imputed missing
baseline data by using chained equations to increase the
precision of the estimates (see web supplement for details).14
We did sensitivity analyses including centre as a random effect
in a generalised linear mixed model and restricting analysis to
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patients with a confirmed diagnosis of rupture only. We also
fitted a complier average causal effects model to obtain an
unbiased estimate of the potential effect if patients had adhered
to trial allocation.15 Specifically, patients who were randomised
to the endovascular strategy, found to be not anatomically
suitable, and treated by open repair had adhered to trial
allocation. Otherwise, we classified reasons for crossover as
non-adherence (see supplement for further details).
We assessed a limited number of pre-specified subgroups (age,
sex, and Hardman index) for differences in effect of the
endovascular and open strategies by using logistic regression
with a test of interaction. Because of the number of statistical
tests, we required a P value below 0.01 to claim strong evidence
of differences between subgroups.
We did secondary endpoint analyses to assess time to in-hospital
mortality and time to discharge by using competing risks
methodology, with in-hospital mortality and discharge as the
two competing risks. We used Gray’s non-parametric test to
compare cumulative incidence curves.16
The cost analysis took a hospital perspective and reported costs
(£GBP, 2011-12) within 30 days of randomisation (web
supplement). We recorded individual resource use data for each
primary hospital admission and readmissions (including
re-interventions) prospectively.
Results
Study population
Between September 2009 and July 2013, 1275 patients (78%
male) were admitted with a diagnosis of ruptured aorto-iliac
aneurysm across the 30 trial centres, and 623 (49%) patients
were randomly assigned to the two study groups. Of the 354
patients who met exclusion criteria, 263 were not considered
for repair, 74 were awaiting elective repair with recent
anatomical assessment of their aneurysm, five had previous
aortic aneurysm repair, and 12 had isolated iliac,
thoracoabdominal, or other complex aneurysms. Ten randomised
patients were excluded from the analysis after review by the
Data Monitoring Committee for breach of inclusion criteria:
two patients had a secondary rupture with previous aneurysm
repair, one patient was admitted electively for aneurysm repair,
three patients were randomised before reaching the trial centre
and the in-hospital clinical diagnosis was not ruptured aneurysm,
and four patients could not be identified in any hospital records.
We assumed that these four patients were randomised before
reaching hospital and did not arrive alive. The consent processes
used for initial consents for the remaining 613 patients were
396 written, 113 verbal with witness, 44 relative/guardian/carer,
and 60 Mental Capacity Act. Figure 1⇓ shows the flow of
patients through the trial. Baseline variables including age, sex,
and Hardman index were balanced between the groups as
randomised (table 1⇓).
Interventions
Of 316 patients randomised to the endovascular strategy, the
diagnosis of rupture was confirmed in 275 (87%), 8 (3%) had
repair of a symptomatic non-ruptured aneurysm in the same
admission, and 33 (10%) had other discharge diagnoses. Table
2⇓ shows operative details, with reasons for open repair. Of the
patients with ruptured or symptomatic aneurysm, 272 had
computed tomography assessed and 174 (64%) were considered
anatomically suitable for EVAR; local reporting of unfavourable
anatomy at the aneurysm neck was the most common reason
for lack of suitability for EVAR (75/84 cases). EVAR was
attempted in 154 patients (four were converted to open repair),
open repair was attempted in 112 other patients (84 anatomically
unsuitable for EVAR, 28 crossovers who were anatomically
suitable for EVAR), 16 patients died before aneurysm repair,
and one patient with a symptomatic aneurysm refused repair
and was discharged.
Of the 297 patients randomised to open repair, the diagnosis of
rupture was confirmed in 261 (88%), 14 (5%) had repair of a
symptomatic intact aneurysm in the same admission, and 22
(7%) had other discharge diagnoses. Table 2⇓ shows operative
details with reasons for crossover to EVAR. EVAR was
attempted in 36 (13%) patients and open repair in 220 (80%)
patients, and 19 patients died before aneurysm repair.
The 55 patients (33 in the endovascular strategy group and 22
in the open repair group) with a final diagnosis unrelated to
abdominal aortic aneurysm had a wide range of other conditions
(ranging from ruptured thoracic aortic aneurysm to urinary tract
infection), and 45/55 had incidental, usually small, abdominal
aortic aneurysms.
Primary outcome
Overall 30 day mortality was 35.4% (112/316) in the
endovascular strategy group and 37.4% (111/297) in the open
repair group (unadjusted odds ratio 0.92, 95% confidence
interval 0.66 to 1.28; P=0.62) (fig 2⇓). Figure 1⇓ shows
mortality for each group by treatment received. After adjustment
for age, sex, and Hardman index, no difference in 30 day
mortality existed between the endovascular strategy and open
repair groups (odds ratio 0.94, 0.67 to 1.33; P=0.73); Hardman
index was strongly predictive of mortality (table C in web
supplement). Inclusion of trial centre in the model did not
change the results, and a separate cohort analysis showed no
significant effects of centre or volume.17 The subgroup analyses
showed no evidence of an interaction with age or Hardman
index. However, the endovascular strategy seemed to be more
effective in women than in men (P=0.02) (fig 2⇓). For women,
30 day mortality was 26/70 (37%) in the endovascular strategy
group and 36/63 (57%) in the open repair group, compared with
86/246 (35%) and 75/234 (32%) for men. The 30 day mortality
rates in patients with confirmed aneurysm rupture were 100/275
(36.4%) in the endovascular strategy group and 106/261 (40.6%)
in the open repair group (P=0.31). In a sensitivity analysis for
623 patients (including the post-randomisation exclusions), 30
day mortality rates were 36% (114/319) in the endovascular
strategy group and 38% (115/304) in the open repair group
(unadjusted odds ratio 0.91, 0.66 to 1.27).
Overall, 549/613 (90%) patients adhered to the trial protocol.
Among 501 patients with ruptured aneurysm who received
aneurysm repair, the 30 day mortality was 84/259 (32%) in the
endovascular strategy group and 87/242 (36%) in the open repair
group (odds ratio 0.86, 0.59 to 1.24). The estimated unbiased
causal odds ratio for a trial in which everyone adhered to the
randomised policy was slightly lower (0.82, 0.51 to 1.32).
Secondary outcomes
Twenty four hour mortality was 22% (68/316) in the
endovascular strategy group and 19% (57/297) in the open repair
group (unadjusted odds ratio 1.15, 0.78 to 1.71) (fig 3⇓). Results
for in-hospital mortality (odds ratio 0.92, 0.66 to 1.27) were
similar to those for 30 day mortality (table 3⇓); the risk
differences for all three mortality outcomes are given in the
supplement. The number and type of re-interventions within 30
days was similar between the randomised groups (table 2⇓), but
the average lengths of stay in critical care and in hospital were
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shorter in the endovascular strategy group (table 4⇓). Ninety
four per cent of discharges within 30 days were directly to home
in the endovascular strategy group compared with only 77% in
the open repair group (P<0.001) (table 3⇓; fig 4⇓). The average
hospital costs within the first 30 days of randomisation were
similar between the randomised groups overall (table 4⇓) and
for pre-specified subgroups or when using alternative
assumptions (web supplement figure A and tables D-F).
Discussion
In this multicentre, pragmatic, randomised trial of patients with
a clinical diagnosis of ruptured abdominal aortic aneurysm, an
endovascular strategy did not reduce either 30 day mortality or
costs overall (30 day mortality 35.4% for endovascular strategy
and 37.4% for open repair) or in those with confirmed rupture
(36.4% and 40.6%). Although 10% of patients crossed over to
the non-allocated treatment group, causal analysis focusing on
compliers showed similar results. However, patients were
discharged earlier and more often to home, and women may
have better survival, with an endovascular strategy.
The observation that women may benefit from an endovascular
strategy could be of particular importance, as the effectiveness
of EVAR for ruptured aneurysm in women has been questioned,
owing to a paucity of evidence.18 Similar proportions of men
and women were included in and excluded from the trial, so our
results are not attributable to selection bias. Moreover, women
may form an increasing proportion of patients presenting with
ruptured aneurysm in future years, as national screening
programmes for aneurysm usually focus on men.
Analysis of secondary endpoints suggested that patients
randomised to an endovascular strategy had reduced stay in
critical care and were discharged home earlier than were patients
randomised to open repair. An endovascular strategy was
associated with a similar cost to open repair, as the shorter
critical care stay and the greater proportion discharged directly
to home offset the additional cost of the endovascular device
and consumables. Unlike in previous trials of elective repair,19
patients in the endovascular strategy group had a similar number
of re-interventions to the open repair group
Comparison with other studies
The IMPROVE trial had a real world design and hence was
fundamentally different from the recent Dutch trial.8All patients
with clinically diagnosed ruptured aneurysm, in whom aneurysm
repair was considered, were eligible for randomisation before
knowledge of aortic anatomy, definitive imaging, or laparotomy,
with a brief consent process, to permit inclusion of
haemodynamically unstable patients (in half, systolic blood
pressures of <90 mm Hg were recorded). The trial randomised
half of all patients presenting with ruptured aneurysm; of those
not randomised, 57% did not undergo repair and a further 17%
had operational reasons for non-randomisation (either staff or
facilities for EVAR unavailable). A core laboratory reviewed
computed tomography scans to verify the diagnosis of rupture,
and although the aneurysms were large (mean diameter >8 cm),
the proportion of patients judged to be anatomically suitable
for endovascular repair was 64%, in keeping with previous
studies of ruptured aneurysm.20 21As the risk of aneurysm rupture
escalates with increasing aortic diameter, the high mean
aneurysm diameter was perhaps not surprising. The escalating
use of statins in this age group also may offer protection from
rupture,1 and may lead to rupture at higher diameters than
previously. That aneurysms of 10 cm or more in diameter did
not cause symptoms and had escaped detection is more
surprising.
Strengths and limitations
The strength of this trial is its size and “real world” design,
starting with the suspicion of ruptured abdominal aortic
aneurysm. In the trial, the clinical diagnosis of rupture was
incorrect in 13% of patients (compared with the 5% predicted
in the power calculation), which illustrates the difficulty in
making a clinical diagnosis of ruptured aneurysm, particularly
when patients had a small aneurysm identified by screening and
presented with classic symptoms of rupture. Although the
mortality in patients who received EVAR (25%) was lower than
that in those who received open surgery (38%), this did not
translate into a lower overall mortality for the patients
randomised to an endovascular strategy. Several factors may
have contributed to this finding, including the
post-randomisation selection of patients to receive EVAR or
open repair, the mortality of patients with non-aortic pathology,
and unstable patients dying before they underwent aneurysm
repair. The subgroup analyses show a direction in favour of
lower mortality with the endovascular strategy in patients with
the highest Hardman index and age. Misjudgement, leading to
conversion from endovascular to open repair, was uncommon
but was associated with a very high mortality (100%). The
suitability of ruptured aneurysm for EVAR is subjective and
will be defined by the aortic morphology, the experience of the
operator, and the range of resuscitation, endovascular, and
anaesthetic techniques available. The importance of resuscitation
and anaesthetic techniques is highlighted in a cohort analysis
of the patients with proven rupture.17 Overall, our findings
suggest that identifying realistic candidates for endovascular
repair is crucial to improving clinical outcomes.
The appropriate time to subject new technologies to a
randomised controlled trial is controversial. The IDEAL
recommendations suggest that a randomised trial should be
considered when an intervention is sufficiently well evolved to
warrant evaluation, but with the expectation that the intervention
will continue to develop.22 Before the IMPROVE trial, uptake
of endovascular repair for ruptured abdominal aortic aneurysm
in the UK was geographically patchy, with a low uptake, and
the procedure was recommended for evaluation purposes only.23
The IMPROVE trial acted as a focus for widespread evaluation
of aneurysm rupture in centres experienced in using EVAR
electively but relatively immature with respect to emergency
EVAR.
Conclusions and policy implications
The question the trial aimed to answer (to which hospital should
patients with suspected ruptured aneurysm be sent?) cannot be
answered robustly until longer term survival estimates and cost
effectiveness evaluations become available. For the moment, it
would seem prudent to send all patients to centres that can offer
both emergency endovascular and open repair, with audited
results. Patients, particularly women, will favour this approach,
as the endovascular strategy offers the potential advantages of
earlier discharge directly to home.
In conclusion, a disparity remains between evidence from well
equipped, highly specialised single centres, systematic reviews,
national datasets, and small randomised clinical trials.4-27 In
IMPROVE, the largest pragmatic randomised trial, 30 day
mortality and costs were similar in the endovascular strategy
and open repair groups. Evaluation of whether the early fringe
benefits of an endovascular strategy translate into longer term
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survival benefit and cost effectiveness is needed before definitive
conclusions can be drawn about the relative merits of the
endovascular strategy (versus open repair) for ruptured
aneurysm.
Writing Committee: Janet T Powell, Imperial College, London, UK;
Michael J Sweeting, University of Cambridge, Cambridge, UK; Matthew
M Thompson, St George’s Hospital, London; Ray Ashleigh, University
Hospitals of South Manchester, Manchester, UK; Rachel Bell, Guy’s
and St Thomas’s Hospital, London; Manuel Gomes, London School of
Hygiene and Tropical Medicine, London; Roger M Greenhalgh, Imperial
College, London; Richard Grieve, London School of Hygiene and
Tropical Medicine; Francine Heatley, Imperial College, London; Robert
J Hinchliffe, St George’s Hospital, London; Simon G Thompson,
University of Cambridge; Pinar Ulug, Imperial College, London.
Contributors: JTP, MG, RG, FH, MJS, SGT, and PU had full access to
the data, and all members of the Writing Committee approved the
decision to submit for publication. JTP is the guarantor.
IMPROVE trial investigators include the following:
Grant applicants: Janet T Powell (chief investigator), Bruce Braithwaite,
Nicholas J Cheshire, Roger M Greenhalgh, Richard J Grieve, Tajek B
Hassan, Robert Hinchliffe, Simon Howell, Fionna Moore, Anthony A
Nicholson, Chee V Soong (deceased), Matt M Thompson, Simon G
Thompson. Data and trial management: Pinar Ulug (project manager),
Francine Heatley (trial manager—maternity cover), Aisha Anjum (trial
monitor). Statistical analyses: Michael J Sweeting, Simon G Thompson.
Health economics costs analyses: Manuel Gomes, Richard J Grieve.
Trial Management Committee: Janet T Powell (chair), Ray Ashleigh,
Manuel Gomes, Roger MGreenhalgh, Richard Grieve, Robert Hinchliffe,
Michael Sweeting, Matt M Thompson, Simon G Thompson, Pinar Ulug
(Francine Heatley). Trial Steering Committee: Ian Roberts (chair), Peter
R F Bell, Anne Cheetham, Jenny Stephany (Alison Halliday). Data
Monitoring and Ethics Committee: CharlesWarlow (chair), Peter Lamont,
Jonathan Moss, Jan Tijssen. Credentialing Committee: Bruce
Braithwaite, Anthony A Nicholson. Core laboratory: Matthew Thompson,
Ray Ashleigh, Luke Thompson.
Regional principal investigators (in order of site start date from earliest
to most recent) (numbers in parentheses indicate the number of patients
entered into the trial):
United Kingdom: Nicholas J Cheshire, Imperial College Healthcare NHS
Trust, London (20); Jonathan R Boyle, Addenbrooke’s Hospital,
Cambridge (40); Ferdinand Serracino-Inglott (J Vince Smyth, Dec
2012-Nov 2013), Manchester Royal Infirmary, Manchester (69); Matt
M Thompson, Robert J Hinchliffe, St George’s Hospital, London (75);
Rachel Bell, Guy’s and St. Thomas’ Hospital, London (81); Noel Wilson,
Kent and Canterbury Hospital, Canterbury (23); Matt Bown (Dec
2010-present), Martin Dennis (to Dec 2010), Leicester Royal Infirmary,
Leicester (18); Meryl Davis, Royal Free Hospital, London (1); Ray
Ashleigh, University Hospital of South Manchester, Manchester (21);
Simon Howell, Leeds General Infirmary, Leeds (23); Michael G Wyatt,
Freeman Hospital, Newcastle (23); Domenico Valenti, King’s College
Hospital, London (2); Paul Bachoo, Aberdeen Royal Infirmary, Aberdeen
(4); Paul Walker, James Cook University Hospital, Middlesbrough (5);
Shane MacSweeney, Queen’s Medical Centre, Nottingham (34);
Jonathan N Davies, Royal Cornwall Hospital, Truro (5); Dynesh Rittoo
(Jan 2012-present), Simon D Parvin (to Dec 2011), Royal Bournemouth
Hospital, Bournemouth (22); Waquar Yusuf, Royal Sussex County
Hospital, Brighton (5); Colin Nice, Queen Elizabeth Hospital, Gateshead
(5); Ian Chetter, Hull Royal Infirmary, Hull (32); Adam Howard,
Colchester General Hospital, Colchester (24); Patrick Chong, Frimley
Park Hospital, Surrey (14); Raj Bhat, Ninewells Hospital, Dundee (8);
David McLain, Royal Gwent Hospital, Newport; Andrew Gordon (Jun
2012-present), Ian Lane (to Jun 2012), University Hospital of Wales,
Cardiff (4); Simon Hobbs, New Cross Hospital, Wolverhampton (3);
Woolagasen Pillay, Doncaster Royal Infirmary, Doncaster (8); Timothy
Rowlands (Nov 2012-present), Amin El-Tahir (to Nov 2012), Royal
Derby Hospital, Derby (13); John Asquith, University Hospital of North
Staffordshire, Stoke-on-Trent (15); Steve Cavanagh, York Hospital,
York (3). Canada: Thomas L Forbes, London Health Sciences Centre,
University of Western Ontario, London, ON (13).
Trial coordinators: Ayoola Awopetu, Sara Baker, Patricia Bourke, Claire
Brady, Joanne Brown, Jennie Bryce, Christine Bufton, Tina Chance,
Angela Chrisopoulou, Marie Cockell, Andrea Croucher, Gail Curran,
Leela Dabee, Nikki Dewhirst, Jo Evans, Andy Gibson, Siobhan Gorst,
Moira Gough, Lynne Graves, Michelle Griffin, Josie Hatfield, Florence
Hogg, Susannah Howard, ThomasHughes, Alex James, DavidMetcalfe,
Michelle Lapworth, Ian Massey, AwadMohalhal, Teresa Novick, Gareth
Owen, Noala Parr, David Pintar, Tom Smith, Sarah Spencer, Claire
Thomson, Orla Thunder, Tom Wallace, Sue Ward, Vera Wealleans,
Lesley Wilson, Janet Woods, Manu Zachariah, Ting Zheng.
Funding: This trial was supported by UKHealth Technology Assessment
award 07/37/64. The views and opinions expressed herein are those
of the authors and do not necessarily reflect those of the National
Institute of Health Research, the National Health Service, or the
Department of Health. Neither the funder nor the sponsor had any role
in study design, data collection and analysis, or interpretation of the
findings.
Competing interests: All members of the writing committee have
completed the ICMJE uniform disclosure form at www.icmje.org/coi_
disclosure.pdf (available on request from the corresponding author) and
declare: no support from any organisation for the submitted work; no
financial relationships with any organisations that might have an interest
in the submitted work in the previous three years; no other relationships
or activities that could appear to have influenced the submitted work.
Ethical approval: Ethical approval in England and Wales was from
South-Central Berkshire Research Ethics Committee 08/H0505/173, in
Scotland from Scotland A Research Ethics Committee 08/MRE00/90,
and in Canada from University of Western Ontario Health Sciences
Research Ethics Board 17698. Approval for the use of routine data for
patients lost to follow-up in England and Wales was obtained from the
National Information Governance Board ECC 4-03 (f) 2012.
Transparency statement: JTP as corresponding author confirms that
this manuscript is an honest, accurate, and transparent account of the
study being reported; that no important aspects of the study have been
omitted; and that any discrepancies from the study as planned (and, if
relevant, registered) have been explained.
Data sharing: Patient level data can be made available from the
corresponding author after authorisation by the Trial Management
Committee. Consent from participants for data sharing was not obtained,
but any shared data will be anonymised.
1 Anjum A, von Allmen R, Greenhalgh R, Powell JT. Explaining the decrease in mortality
from abdominal aortic aneurysm rupture. Br J Surg 2012;99:637-45.
2 Lindholt JS, Sogaard R, Laustsen J. Prognosis of ruptured abdominal aortic aneurysms
in Denmark from 1994-2008. Clin Epidemiol 2012;4:111-3.
3 Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured
abdominal aortic aneurysm repair. Br J Surg 2002;89:714-30.
4 Egorova N, Giacovelli J, Greco G, Gelijns A, Kent CK, McKinsey JF. National outcomes
for the treatment of ruptured abdominal aortic aneurysm: comparison of open versus
endovascular repairs. J Vasc Surg 2008;48:1092-100.
5 Holt PJ, Karthikesalingam A, Poloniecki JD, Hinchliffe RJ, Loftus IM, Thompson MM.
Propensity scored analysis of outcomes after ruptured abdominal aortic aneurysm. Br J
Surg 2010;97:496-503.
6 Schermerhorn ML, Bensley RP, Giles KA, Hurks R, O Malley AJ, Cotterill P, et al. Changes
in abdominal aortic aneurysm rupture and short-termmortality, 1995-2008: a retrospective
observational study. Ann Surg 2012;256:651-8.
7 Hinchliffe RJ, Bruijstens L, MacSweeney ST, Braithwaite BD. A randomised trial of
endovascular and open surgery for ruptured abdominal aortic aneurysm—results of a
pilot study and lessons learned for future studies. Eur J Vasc Endovasc Surg
2006;32:506-13.
8 Reimerink JJ, Hoornweg LL, Vahl AC, Wisselink W, van den Broek TA, Legemate DA, et
al. Endovascular repair versus open repair of ruptured abdominal aortic aneurysms: a
multicenter randomized controlled trial. Ann Surg 2013;258;248-56.
9 Mell MW, Callcut RA, Bech F, Delgado MK, Staudenmayer K, Spain DA, et al. Predictors
of emergency department death for patients presenting with ruptured abdominal aortic
aneurysm. J Vasc Surg 2012;56:651-5.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:f7661 doi: 10.1136/bmj.f7661 (Published 13 January 2014) Page 5 of 12
RESEARCH
What is already known on this topic
For selected patients with ruptured abdominal aortic aneurysm, national datasets and single centre series suggest that endovascular
repair is associated with a lower operative mortality than open surgical repair
However, two small randomised trials have failed to show any difference in operative mortality between the two types of repair
Many vascular centres cannot offer emergency endovascular repair at all times
What this study adds?
Similar overall 30 day mortality was seen with an endovascular strategy (35%) and open surgical repair (37%)
However, the study starts to identify patients who may benefit from an endovascular strategy (such as women) and shows that, after
30 days, the endovascular strategy did not cost more than open repair and offers the patient earlier discharge home
10 Brattheim BJ, Eikemo TA, Altreuther M, Landmark AD, Faxvaag A. Regional disparities
in incidence, handling and outcomes of patients with symptomatic and ruptured abdominal
aortic aneurysms in Norway. Eur J Vasc Endovasc Surg 2012;44:267-72.
11 Mastracci TM, Garrido-Olivares L, Cinà CS, Clase CM. Endovascular repair of ruptured
abdominal aortic aneurysms: a systematic review and meta-analysis. J Vasc Surg
2008;47:214-21.
12 Hardman DT, Fisher CM, Patel MI, Neale M, Chambers J, Lane R, et al. Ruptured
abdominal aortic aneurysms: who should be offered surgery? J Vasc Surg 1996;23:123-9.
13 Acosta S, Ogren M, Bergqvist D, Lindblad B, Dencker M, Zdanowski Z. The Hardman
index in patients operated on for ruptured abdominal aortic aneurysm: a systematic review.
J Vasc Surg 2006;44:949-54.
14 White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and
guidance for practice. Stat Med 2011;30:377-99.
15 Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in
randomized clinical trials. Stat Med 1997;16:1017-29.
16 Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing
risk, Ann Stat 1988;16:1141-54.
17 IMPROVE trial investigators. Observations from the IMPROVE trial concerning improving
the clinical care of patients with ruptured abdominal aortic aneurysm. Br J Surg
[forthcoming].
18 De Rango P, Lenti M, Cieri E, Simonte G, Cao P, Richards T, et al. Association between
sex and perioperative mortality following endovascular repair for ruptured abdominal aortic
aneurysms. J Vasc Surg 2013;57:1684-92.
19 Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG. Comparison of
endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm
(EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet
2004;364:843-8.
20 Hoornweg LL, Wisselink W, Vahl A, Balm R. The Amsterdam Acute Aneurysm Trial:
suitability and application rate for endovascular repair of ruptured abdominal aortic
aneurysms. Eur J Vasc Endovasc Surg 2007;33:679-83.
21 Dick F, Diehm N, Opfermann P, von Allmen R, Tevaearai H, Schmidli J. Endovascular
suitability and outcome after open surgery for ruptured abdominal aortic aneurysm. Br J
Surg 2012;99:940-7.
22 McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC. No surgical
innovation without evaluation: the IDEAL recommendations. Lancet 2009;374:1105-13.
23 National Institute for Health and Clinical Excellence. Endovascular stent-grafts for the
treatment of abdominal aortic aneurysms. NICE, 2009 (available at http://guidance.nice.
org.uk/TA167).
24 Mayer D, Aeschbacher S, Pfammatter T, Veith FJ, Norgren L, Magnuson A, et al. Complete
replacement of open repair for ruptured abdominal aortic aneurysms by endovascular
aneurysm repair: a two-center 14-year experience. Ann Surg 2012;256:688-95.
25 Karkos CD, Sutton AJ, BownMJ, Sayers RD. Ameta-analysis andmetaregression analysis
of factors influencing mortality after endovascular repair of ruptured abdominal aortic
aneurysms. Eur J Vasc Endovasc Surg 2011;42:775-86.
26 Mayer D, Pfammatter T, Rancic Z, Hechelhammer L, Wilhelm M, Veith FJ, et al. 10 years
of emergency endovascular aneurysm repair for ruptured abdominal aortoiliac aneurysms:
lessons learned. Ann Surg 2009;249:510-5.
27 Mehta M, Byrne J, Darling RC III, Roddy SP, Taggert JB, Sternbach Y, et al. Endovascular
repair of ruptured infrarenal abdominal aortic aneurysm is associated with lower 30-day
mortality and better 5-year survival rates than open surgical repair. J Vasc Surg
2013;57:368-75.
Accepted: 17 December 2013
Cite this as: BMJ 2014;348:f7661
This is an Open Access article distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute,
remix, adapt, build upon this work non-commercially, and license their derivative works
on different terms, provided the original work is properly cited and the use is
non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:f7661 doi: 10.1136/bmj.f7661 (Published 13 January 2014) Page 6 of 12
RESEARCH
Tables
Table 1| Baseline characteristics of patients by randomised group. Values are numbers (percentages) unless stated otherwise
Open repair (n=297)Endovascular strategy (n=316)MissingVariable
76.7 (7.8)76.7 (7.4)0Mean (SD) age, years
234/297 (79)246/316 (78)0Male sex
(n=295)(n=306)12Mean (SD) admission blood pressure, mm Hg:
110.4 ( 31.2)110.3 (32.9)Systolic
66.8 (22.5)65.3 (21.4)Diastolic
11.1 (2.3); (n=295)11.2 (2.5); (n=312)6Mean (SD) admission haemoglobin (g/dL)
115 (93-151); (n=288)117 (94-152); (n=312)13Median (interquartile range) admission creatinine,
µM/L
23/270 (8)22/291 (8)52Acute myocardial ischaemia on electrocardiogram
21/281 (7)29/305 (10)27Loss of consciousness
(n=257)(n=282)74Hardman index* (0-5):
69 (27)93 (33)0
126 (49)130 (46)1
48 (19)46 (16)2
12 (5)11 ( 4)3
2 (1)2 (1)4
0 (0)0 (0)5
266/297 (90)305/316 (97)0Computed tomography scan performed
81 (18); (n=264)84 (19); (n=263)86Mean (SD) maximum aortic diameter, mm
*Scores 1 point each for age >76 years, acute myocardial ischaemia on electrocardiogram, haemoglobin <9.0 g/dL, creatinine >190 µM/L, and loss of consciousness
after admission.
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Table 2| Operative details for patients with ruptured and symptomatic abdominal aortic aneurysm by randomised group, including reasons
for not receiving allocated treatment. Values are numbers (percentages) unless stated otherwise
Open repair (n=275)Endovascular strategy (n=283)MissingVariable
Median (interquartile range) time from randomisation to theatre admission*:
37 (22-62); (n=240)47 (28-73); (n=259)5Rupture (minutes)
3.0 (1.5-17.6); (n=13)3.6 (3.1-15.6); (n=6)2Symptomatic (hours)
(n=256)(n=267)35Lowest systolic pressure before arrival in operating suite:
41 (16)54 (20)<70 mm Hg
73 (29)83 (31)70-89 mm Hg
142 (55)130 (49)≥90 mm Hg
239/275 (87)254/283 (90)Complied with allocated treatment:
—150† (54)EVAR
—4 (1)EVAR converted to open
—84 (30)Open repair because unsuitable for EVAR
220 (80)—Open repair
19 (7)16 (6)Died before repair
0 (0)1 (0)Refused repair of symptomatic aneurysm
EVAR in 36/275 (13)Open repair in 28/283 (10)Reasons for not complying with allocated treatment:
14Operational reason‡
020Rapid clinical deterioration
160Medical comorbidities
90Anaesthetist’s decision
22Patient’s or clinician’s preference
82Other
(n=254)(n=262)6Type of anaesthesia:
237 (93)176 (67)General
2 (1)32 (12)Local to general
15 (6)54 (21)Local
(n=235)(n=238)8Re-interventions in 30 days§:
187 (80)195 (82)0
33 (14)28 (12)1
15 (6)15 (6)≥2
9Reasons for re-intervention:
11 (5)9 (4)Control of bleeding
17 (7)19 (8)Limb ischaemia
19 (8)14 (6)Mesenteric ischaemia
12 (5)14 (6)Abdominal compartment syndrome
26 (11)8 (3)Other
1 (0)2 (1)Unknown
EVAR=emergency endovascular aneurysm repair.
*For 525 patients who arrived alive for aneurysm repair.
†Graft configurations used were 35 aorto-uni-iliacs, 104 bifurcated, 2 tube, 9 missing.
‡Essential staff or facilities unavailable.
§For 481 patients who left theatre alive after aneurysm repair.
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Table 3| Place of discharge by randomised group and in-hospital mortality. Values are numbers (percentages)
Open repair group (n=297)Endovascular strategy group (n=316)Outcome
183 (62)201 (64)Discharged alive from trial hospital
Place of discharge:
141 (77)189 (94)Home
28 (15)7 (3)Another hospital—routine bed
1 (1)0 (0)Another hospital—intensive care
3 (2)0 (0)Nursing home
3 (2)1 (1)Residential home
0 (0)1 (1)Sheltered accommodation
7 (4)3 (1)Other
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Table 4| Resource use and costs to 30 days by randomised group. Values are mean (SD) unless stated otherwise
Open repair (n=297)Endovascular strategy (n=316)Cost component
Primary admission:
73 (157)93 (370)Time in emergency room (mins)*
119 (51)136 (138)Cost (£)
2523 (2036)4337 (2915)Devices and consumables
180 (107)156 (100)Time in theatre (mins)†
2101 (1264)2050 (1290)Cost (£)
6.3 (7.7)4.2 (5.9)Days in critical care
8100 (11 020)5249 (8779)Cost (£)
5.7 (6.7)5.2 (5.0)Days on routine ward‡
1518 (1814)1425 (1591)Cost (£)
48 (16)44 (14)No (%) re-interventions
224 (1042)172 (581)Cost (£)
Readmissions:
5 (1.9)6 (1.7)No (%) readmissions
34 (290)64 (554)Cost (£)
12.2 (10.2)9.8 (9.0)Total hospital stay (days)
14 619 (12 353)13 433 (10 354)Total cost (£)
−1186 (−2997 to 625)Incremental cost (£) (95% CI)
For approximately 8% of patients, resource use data were missing; results reported are following multiple imputations. Unit costs are reported in table D in web
supplement.
*Includes costs of computed tomography and contrast agent.
†Unit costs of theatre time were £885/hour for patients who actually received emergency endovascular aneurysm repair (EVAR) procedure and £675/hour for
those who actually received open repair and reflected the additional staff required for EVAR procedure (for further details see supplement on IMPROVE website).
‡Patients who did not undergo aneurysm repair (8.9%) were assumed to stay on routine ward throughout hospital admission (further details of subgroup and
sensitivity analyses are available in web supplement figure A and tables E and F).
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Figures
Fig 1 CONSORT diagram showing flow of patients through trial, with 30 day mortality for each group. AAA=abdominal
aortic aneurysm; EVAR=endovascular aneurysm repair. *Patients breaching trial protocol
Fig 2 30 day mortality by randomised group with subgroup analyses for age, sex, and Hardman index. Interaction P values
consider age and Hardman index as continuous variables
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Fig 3 Time to 30 day death by randomised group
Fig 4 Cumulative incidence of being discharged directly to home by randomised group
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